Effects of MDCO-216 on plasma lipid and lipoprotein

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
Subjects carrying the apolipoprotein A-I Milano (apoA-IM) variant have a low incidence of cardiovascular disease despite a severe hypoalphalipoproteinemia, due to an increased cholesterol efflux capacity of apoA-IM-containing HDL. This led to the development of MDCO-216, a recombinant HDL containing the apoA-IM variant which has been tested in healthy volunteers and patients with stable CAD. The infusion of MDCO-216 leads to changes in plasma lipids in both groups of subjects. The main changes include (i) increase of plasma free cholesterol (FC) concentrations, due to an increased FC content in HDL, LDL and VLDL, (ii) increase of triglycerid...